28-06-2023 | Hepatitis D
Current and Evolving Management of Chronic Hepatitis Delta Virus (HDV) Infection
Authors:
Maria Paola Anolli, Elisabetta Degasperi, Pietro Lampertico
Published in:
Current Hepatology Reports
|
Issue 3/2023
Login to get access
Abstract
Purpose of Review
This review aims to examine the current and evolving management of chronic hepatitis delta virus (HDV) infection, a severe form of viral hepatitis characterized by accelerated liver disease progression, leading to cirrhosis and its complications. Previously, off-label interferon (IFN) administration was the only treatment option for HDV infection, with limited effectiveness and several side effects.
Recent Findings
The discovery of the entry inhibitor bulevirtide (BLV) has been a breakthrough in HDV treatment, showing high rates of viral suppression in clinical trials and in real-life studies. Other compounds, such as lonafarnib and new anti-HBV drugs, are under development to provide alternative or combined treatment strategies.
Summary
Since HDV’s discovery, more than 40 years ago, the current treatment scenario for HDV is rapidly evolving: while BLV is the first approved drug for HDV treatment, with proven effectiveness also in real-life settings, many other compounds are currently under investigation.